{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dummy+tablets&page=2", "query": { "intervention": "Dummy tablets", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dummy+tablets&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-21T13:56:40.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03785756", "title": "Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Ibuprofen 300 mg Oral Tablet", "type": "DRUG" }, { "name": "Ibuprofen 200 mg Oral Tablet", "type": "DRUG" }, { "name": "Placebo of PR tablet", "type": "DRUG" }, { "name": "Placebo of IR tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Reckitt Benckiser Healthcare (UK) Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 280, "start_date": "2019-04-29", "completion_date": "2020-02-28", "has_results": true, "last_update_posted_date": "2024-06-03", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03785756" }, { "nct_id": "NCT01016678", "title": "Treximet Early Intervention Adolescent Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Treximet", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Premiere Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 104, "start_date": "2010-03", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2016-05-04", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 4, "location_summary": "West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more", "locations": [ { "city": "West Palm Beach", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01016678" }, { "nct_id": "NCT00708162", "title": "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Elvitegravir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "EVG placebo", "type": "DRUG" }, { "name": "RAL placebo", "type": "DRUG" }, { "name": "Background regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 724, "start_date": "2008-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-30", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 94, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00708162" }, { "nct_id": "NCT00428090", "title": "Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Rosiglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 862, "start_date": "2007-02-27", "completion_date": "2008-09-05", "has_results": true, "last_update_posted_date": "2017-05-19", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Reseda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00428090" }, { "nct_id": "NCT02081534", "title": "Dose Finding Study to Treat High Phosphate Levels in the Blood.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperphosphatemia" ], "interventions": [ { "name": "AZD1722", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ardelyx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 162, "start_date": "2014-03", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2020-09-14", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 16, "location_summary": "Downey, California • Los Angeles, California • Sacramento, California + 13 more", "locations": [ { "city": "Downey", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02081534" }, { "nct_id": "NCT05156281", "title": "Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Remibrutinib", "type": "DRUG" }, { "name": "Teriflunomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1007, "start_date": "2021-12-13", "completion_date": "2030-10-30", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hanford", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156281" }, { "nct_id": "NCT05055128", "title": "A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Erosive Esophagitis" ], "interventions": [ { "name": "X842", "type": "DRUG" }, { "name": "X842 Dummy", "type": "DRUG" }, { "name": "Lansoprazole", "type": "DRUG" }, { "name": "Lansoprazole Dummy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cinclus Pharma Holding AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 248, "start_date": "2021-08-11", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05055128" }, { "nct_id": "NCT05147220", "title": "Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Remibrutinib", "type": "DRUG" }, { "name": "Teriflunomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1000, "start_date": "2021-12-16", "completion_date": "2030-10-30", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 52, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05147220" }, { "nct_id": "NCT00852540", "title": "Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Skin Infections, Bacterial" ], "interventions": [ { "name": "Retpamulin Ointment, 1%", "type": "DRUG" }, { "name": "Linezolid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stiefel, a GSK Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": null, "sex": "ALL", "summary": "2 Months and older" }, "enrollment_count": 410, "start_date": "2009-04", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2017-03-27", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 53, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Bentonville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Paragould", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00852540" }, { "nct_id": "NCT00781391", "title": "Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stroke", "Atrial Fibrillation", "Embolism" ], "interventions": [ { "name": "warfarin tablets", "type": "DRUG" }, { "name": "Edoxaban tablets (high dose regimen-60mg)", "type": "DRUG" }, { "name": "Edoxaban tablets (low dose regimen-30mg)", "type": "DRUG" }, { "name": "placebo warfarin", "type": "DRUG" }, { "name": "placebo edoxaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 21105, "start_date": "2008-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-21T13:56:40.543Z", "location_count": 316, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Lake Havasu City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00781391" } ] }